Lexeo Therapeutics (LXEO) Current Leases (2022 - 2026)

Lexeo Therapeutics has reported Current Leases for 5 years, with the latest figure at $528000.0 in Q1 2026.

• Quarterly Current Leases fell 75.16% year-over-year to $528000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $528000.0 (down 75.16% YoY) and the FY2025 annual result came in at $2.2 million, up 2.71% from the prior year.
• Current Leases slipped to $528000.0 in Q1 2026 per LXEO's latest filing, from $2.2 million in the prior quarter.
• Over five years, Current Leases peaked at $2.3 million in Q4 2022 and troughed at $518000.0 in Q4 2023.
• A 5-year average of $1.1 million and a median of $570000.0 in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2025: Current Leases slumped 77.35% in 2023, then jumped 305.73% in 2025.
• Over 5 years, Current Leases stood at $2.3 million in 2022, then plunged by 77.35% to $518000.0 in 2023, then soared by 305.41% to $2.1 million in 2024, then advanced by 2.71% to $2.2 million in 2025, then slumped by 75.52% to $528000.0 in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $528000.0, $2.2 million, and $568000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.